Real-World Data on the Incidence of Stroke, Myocardial Infarction, and Mortality Among Nonvalvular Atrial Fibrillation Patients in Türkiye: New Oral Anticoagulants-TURKey Study

Basit Öğe Kaydı
dc.authoridSinan, Umit/0000-0002-4837-7099
dc.authoridŞahin, Mahmut/0000-0003-3765-748X
dc.authoridCanpolat, Ugur/0000-0002-4250-1706
dc.authoridAskin, Lutfu/0000-0001-7768-2562
dc.authorwosidSinan, Umit/A-7003-2017
dc.authorwosidŞahin, Mahmut/IQS-8407-2023
dc.authorwosidCanpolat, Ugur/S-3482-2018
dc.authorwosidAskin, Lutfu/H-1047-2018
dc.contributor.authorUnlu, Serkan
dc.contributor.authorAltay, Servet
dc.contributor.authorGedikli, Omer
dc.contributor.authorOzden, Ozge
dc.contributor.authorCanpolat, Ugur
dc.contributor.authorAskin, Lutfu
dc.contributor.authorYayla, Cagri
dc.date.accessioned2024-06-12T10:51:56Z
dc.date.available2024-06-12T10:51:56Z
dc.date.issued2024
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Atrial fibrillation (AF) is strongly associated with an increased risk of isch- emic events. Anticoagulation focuses on reducing the risk of embolism. Guideline recom- mended CHA2DS2-VASc scoring system is most widely used; however, different scoring systems do exist. Thus, we sought to assess the impact of anticoagulant treatment and different scoring systems on the development of stroke, myocardial infarction, and allcause mortality in patients with nonvalvular AF. Methods: The present study was designed as a prospective cohort study. The enrollment of the patients was conducted between August 1, 2015, and January 1, 2016. The followup period was defined as the time from enrollment to the end of April 1, 2017, which also provided at least 12 months of prospective follow-up for each patient. Results: A total of 1807 patients with AF were enrolled. During the follow-up, 2.7% (48) of patients had stroke, 0.8% (14) had myocardial infarction, and 7.5% (136) died. The antico- agulation and risk factors in AF (ATRIA) score had a better accuracy for the prediction of stroke compared to other scoring systems (0.729, 95% CI, 0.708-0.750, P < .05). Patients under low -dose rivaroxaban treatment had significantly worse survival (logrankP < .001). Age, CHA2DS2-VASc score, R2CHADS2 score, ATRIA score, chronic heart failure, prior stroke, and being under low -dose rivaroxaban treatment were independent predictors of clinical endpoint (P < .001). Conclusion: Low -dose rivaroxaban treatment was independently and strongly associated with the combined clinical endpoint. Furthermore, the ATRIA score proved to be a stronger predictor of stroke in the Turkish population.en_US
dc.identifier.doi10.14744/AnatolJCardiol.2023.3389
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue1en_US
dc.identifier.pmid37888785en_US
dc.identifier.scopus2-s2.0-85181560137en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2023.3389
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18542
dc.identifier.volume28en_US
dc.identifier.wosWOS:001179751900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofAnatolian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnticoagulant Agentsen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectDeathen_US
dc.subjectIschemic Strokeen_US
dc.subjectMyocardial Infarctionen_US
dc.subjectRisken_US
dc.subjectPreventionen_US
dc.subjectValidationen_US
dc.titleReal-World Data on the Incidence of Stroke, Myocardial Infarction, and Mortality Among Nonvalvular Atrial Fibrillation Patients in Türkiye: New Oral Anticoagulants-TURKey Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu